Whether this is explained by pharmacodynamic differences in vivo, or because IDH inhibitors and Venetoclax target different cell types in genetically and epigenetically heterogenous AML tumours remains under investigation. This evidence concerns the gene IDH2 and acute myeloid leukemia.